^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Hematological Malignancies

    Related cancers:
    1d
    Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma (clinicaltrials.gov)
    P=N/A, N=144, Recruiting, University Health Network, Toronto | N=80 --> 144 | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Enrollment change • Trial completion date • Trial primary completion date
    1d
    KSV01 Injection for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=30, Recruiting, TCRx Therapeutics Co.Ltd
    New P1 trial
    1d
    Real MM: STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA (clinicaltrials.gov)
    P4, N=450, Active, not recruiting, University of Turin, Italy | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    lenalidomide • bortezomib • prednisone • melphalan • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • dexamethasone injection
    1d
    Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial (clinicaltrials.gov)
    P3, N=668, Recruiting, University of Rochester | Phase classification: P=N/A --> P3 | N=960 --> 668 | Trial completion date: Dec 2028 --> May 2027 | Trial primary completion date: Jun 2028 --> May 2027
    Phase classification • Enrollment change • Trial completion date • Trial primary completion date
    1d
    Virtual Rehabilitation for Cancer Survivors (clinicaltrials.gov)
    P=N/A, N=388, Recruiting, University Health Network, Toronto | Trial completion date: Aug 2025 --> Nov 2026 | Trial primary completion date: May 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    1d
    Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant (clinicaltrials.gov)
    P2, N=120, Suspended, University of Utah | Recruiting --> Suspended | Trial primary completion date: Jan 2026 --> May 2026
    Trial suspension • Trial primary completion date
    |
    CD34 (CD34 molecule)
    1d
    A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (clinicaltrials.gov)
    P1, N=64, Recruiting, AstraZeneca | N=20 --> 64
    Enrollment change
    |
    AZD0120
    1d
    WF-1804CD: Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors (clinicaltrials.gov)
    P=N/A, N=600, Completed, Wake Forest University Health Sciences | Active, not recruiting --> Completed
    Trial completion
    1d
    A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P4, N=44, Completed, Pfizer | Active, not recruiting --> Completed
    Trial completion
    |
    CD22 (CD22 Molecule)
    |
    CD22 positive
    |
    Besponsa (inotuzumab ozogamicin)
    1d
    OPTIMUS-EL: Phase II Trials of Letermovir Prophylaxis in Patients With RRMM Undergoing Elranatamab Therapy (clinicaltrials.gov)
    P2, N=40, Recruiting, Seoul National University Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Elrexfio (elranatamab-bcmm)
    1d
    Clinical Study Comparing Different Strategies to Increase Adherence to Oral Therapies in Oncohematology (clinicaltrials.gov)
    P=N/A, N=124, Completed, Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Recruiting --> Completed | Trial completion date: May 2023 --> Nov 2025 | Trial primary completion date: May 2023 --> Nov 2025
    Trial completion • Trial completion date • Trial primary completion date
    1d
    Acquired MYC rearrangement potentially associated with ibrutinib resistance in mantle cell lymphoma. (PubMed, Virchows Arch)
    In conclusion, our findings suggest that c-Myc overexpression and MYC rearrangement are associated with ibrutinib resistance in MCL. Detecting MYC rearrangement in selected MCL cases could be critical for optimizing treatment strategies and improving patient outcomes.
    Journal • IO biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6) • CD5 (CD5 Molecule) • MME (Membrane Metalloendopeptidase) • SOX11 (SRY-Box Transcription Factor 11)
    |
    Imbruvica (ibrutinib)